China Neurovascular Devices Market, By Device (Cerebral Embolization and Aneurysm Coiling Devices, Cerebral Angioplasty and Stenting Systems, Neurothrombectomy Devices, Support Devices, Trans Radial Access Devices), By Therapeutic Application (Stroke, Cerebral Artery, Cerebral Aneurysm, Others), By End User (Hospitals, Specialty Clinics, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

China Neurovascular Devices Market was valued at USD 255.56 Million in 2024 and is expected to reach USD 392.01 Million by 2030 with a CAGR of 7.35%. The China Neurovascular Devices Market is undergoing a strategic inflection point, shaped by a surge in stroke-related cases, evolving clinical practices, and accelerated adoption of advanced intervention technologies. The rising burden of ischemic and hemorrhagic strokes particularly among the country’s aging population is driving increased demand for high-precision neurovascular devices across a widening spectrum of hospitals, from top-tier urban centers to emerging regional facilities.

China is positioning itself as a critical growth engine for neurovascular device manufacturers, underpinned by a favorable policy environment, expanding reimbursement access, and a deliberate national push to build a self-reliant medtech ecosystem. Market participants that localize product offerings, align with government-supported stroke care models, and invest in physician training and regional deployment strategies are likely to gain competitive traction and unlock scalable, long-term value in this rapidly evolving landscape.

Key Market Drivers

Rising Stroke Prevalence and Aging Population

The rising incidence of stroke, combined with China’s rapidly aging population, is acting as a powerful long-term catalyst for the growth of the China Neurovascular Devices Market. This demographic and disease burden convergence is not only expanding the clinical need for advanced intervention tools but also reshaping how hospitals, policymakers, and manufacturers approach neurovascular care. China is undergoing a pronounced demographic transition, with individuals aged 60 and above accounting for more than 20% of the total population by the end of 2023. Projections indicate this segment will surpass 30% by 2035, reflecting a structural shift toward a senior-dominated population. This aging trend is expected to exert substantial pressure on the healthcare system, particularly in areas like neurovascular care, where age-related cerebrovascular conditions are most prevalent and resource-intensive. Age-related vascular degeneration, hypertension, diabetes, and sedentary lifestyles are significantly increasing stroke susceptibility. Ischemic stroke alone accounts for over 70% of total stroke cases in China, most commonly affecting those aged 60+. This expanding elderly population directly increases the volume of patients requiring interventional therapies such as mechanical thrombectomy, aneurysm coiling, and flow diversion procedures, thereby driving consistent demand for neurovascular devices.

China faces one of the heaviest stroke burdens globally, recording over 3 million new stroke cases each year and managing a population of more than 13 million stroke survivors in need of continuous care and rehabilitation. This epidemiological landscape positions China as a critical focal point for stroke management, underscoring an urgent demand for scalable, high-impact prevention frameworks and advanced interventional treatment solutions to reduce long-term disability and healthcare system strain. Tertiary hospitals and designated stroke centers are reporting a notable rise in acute stroke interventions, particularly within the critical 6-hour treatment window. Mechanical thrombectomy procedures, once limited to top-tier facilities, are now expanding into regional and county-level hospitals. This uptick in procedural throughput is contributing directly to higher device adoption across a broadening range of institutions. China’s central and provincial governments have identified stroke as a national health priority due to its economic burden and public health impact. Stroke accounts for the highest rate of disability-adjusted life years (DALYs) in the country, creating long-term financial pressure on families and the healthcare system. Expanded insurance coverage for stroke-related interventions. Supported the establishment of certified stroke centers with the capacity to perform neurointerventional procedures. Encouraged adoption of cost-effective technologies that can reduce disability rates in the aging population. These policies have created a strong reimbursement and infrastructure framework that encourages hospitals to invest in neurovascular equipment and training.

Urbanization and Improved Diagnostic Penetration

As of 2024, 67% of China’s population resides in urban areas, reflecting the country’s rapid and ongoing urban transformation. Forecasts suggest this figure will climb to 75–80% by 2035, signaling a major shift in healthcare demand toward urban centers. This urban concentration is expected to drive significant investments in advanced medical infrastructure, including neurovascular intervention capabilities, across both established metros and fast-growing secondary cities. The construction of Class II and III hospitals in newly urbanized districts, Establishment of comprehensive stroke centers and emergency care networks, Development of specialized departments equipped for neurointerventional procedures. As a result, access to minimally invasive stroke interventions is improving across a broader geographic footprint. More urban hospitals are adopting DSA labs, employing trained neurointerventionists, and integrating device-based stroke management protocols, thereby driving demand for neurovascular tools such as stent retrievers, flow diverters, and coils. Urban healthcare facilities now have greater access to advanced imaging modalities including CT angiography (CTA), magnetic resonance angiography (MRA), and digital subtraction angiography (DSA) which are critical for diagnosing neurovascular conditions such as ischemic stroke, cerebral aneurysm, and AVMs (arteriovenous malformations). Early and accurate diagnosis leads to timely intervention, increasing utilization of interventional devices. Better imaging coverage allows for more precise treatment planning, boosting demand for high-precision tools like microcatheters and navigation systems. Widespread access to DSA machines in urban hospitals has facilitated the rise of mechanical thrombectomy procedures, which are now being performed with greater frequency in both public and private facilities.

Urbanization has also led to higher levels of health literacy, greater health insurance coverage, and a cultural shift toward preventive healthcare. As a result, there is increasing demand for routine neurovascular screenings, especially among the middle-aged and elderly populations at high risk for stroke. Many urban employers, community clinics, and insurance-backed health programs are offering annual check-ups that include brain scans and vascular screenings. This is enabling the early identification of asymptomatic aneurysms, carotid artery stenosis, and cerebral vessel abnormalities conditions that often require device-based intervention. This preventive diagnostic push is expanding the neurovascular market beyond emergency care into elective and preemptive procedures, opening new avenues for device utilization. The impact of urbanization extends beyond major metropolitan centers. Suburban and peri-urban districts are rapidly developing secondary and tertiary hospitals that are increasingly equipped to perform neurovascular procedures. These hospitals are emerging as new demand hubs for device manufacturers, particularly those offering cost-effective, scalable technologies. Manufacturers that can supply: Portable imaging-compatible devices, Training programs for newly formed stroke teams, Support for digital diagnostics and tele-radiology platforms are uniquely positioned to scale alongside this urban-medical expansion.

Download Free Sample Report

Key Market Challenges

Uneven Access to Neurointerventional Care Across Regions

China’s healthcare delivery is highly centralized in urban Tier I cities, such as Beijing, Shanghai, and Guangzhou. In contrast, rural and lower-tier cities often lack the necessary infrastructure, trained specialists, and funding to offer advanced neurovascular procedures.

Limits device utilization in underdeveloped regions. Creates regional disparities in procedure volumes and treatment outcomes. Delays national scalability for device manufacturers seeking uniform penetration. Shortage of neurointerventionists in secondary hospitals. Insufficient investment in high-end imaging systems and DSA labs. Inconsistent implementation of government policies across provinces.

Regulatory and Reimbursement Hurdles

Although China has made strides in regulatory reform, the approval and reimbursement pathways for neurovascular devices remain complex, time-consuming, and less transparent compared to developed markets. Moreover, high-end imported devices are often excluded or only partially covered under national insurance plans. Slows down market entry for innovative or foreign-developed devices. Limits patient affordability, especially for expensive interventions like mechanical thrombectomy or flow diversion. Forces manufacturers to engage in price-cutting strategies that compress margins. Lengthy clinical trial and registration requirements for Class III devices. Varied reimbursement rules between urban employee insurance and rural schemes. Government’s strong push for domestic substitution, creating entry barriers for foreign brands.

Key Market Trends

Rise of Smart Neurovascular Devices Integrated with AI and Robotics

China is rapidly embracing digital transformation in neurovascular care, with increasing integration of AI-powered imaging platforms, robotic-assisted interventions, and real-time data analytics in endovascular procedures.

AI algorithms are being developed to aid in early stroke detection, automated clot localization, and treatment planning, significantly reducing time-to-intervention. Robotic-assisted systems offer greater precision, especially in complex navigation through cerebral vessels, and are expected to gain ground in high-volume stroke centers. Domestic medtech start-ups and research institutions are collaborating to localize AI solutions specifically tailored for the Chinese population and hospital workflows. Companies that integrate intelligent capabilities into device platforms, such as smart coils or AI-guided thrombectomy systems, will be well-positioned to gain market share and differentiate in an increasingly tech-driven landscape.

Cross-Border Innovation Partnerships and Localized Co-Development

Rather than relying solely on imported technologies, China is increasingly pursuing joint ventures, technology licensing, and co-development models between global innovators and local medtech firms. This is catalyzed by regulatory encouragement for technology transfer and domestic capability building.

Global neurovascular device companies are partnering with Chinese firms to localize advanced devices, streamline approvals, and reduce costs. Local companies are investing in R&D hubs and clinical trial networks to co-develop customized products that align with domestic clinical needs and reimbursement realities. Firms engaging in collaborative R&D and localized manufacturing will gain regulatory advantages, reduce import dependency, and accelerate adoption particularly in price-sensitive public hospitals.

Growth of Digital Therapeutics and Remote Patient Monitoring

The rise of digital therapeutics (DTx) and remote patient monitoring (RPM) is transforming Vietnam’s approach to chronic disease management and post-treatment care. These solutions provide continuous, tech-enabled medical supervision, reducing hospital dependency and improving long-term patient outcomes.

Digital therapeutics are software-driven treatments designed to supplement or replace traditional medication. In Vietnam, mobile-based DTx solutions are being developed for diabetes management, mental health support, and rehabilitation programs. These tools provide behavioral coaching, medication adherence reminders, and real-time health tracking to empower patients in self-managing their conditions. Smartwatches, biosensors, and IoT-enabled medical devices are gaining traction, enabling continuous monitoring of vital signs such as heart rate, blood pressure, glucose levels, and oxygen saturation. This is particularly beneficial for elderly patients, post-surgery recovery, and high-risk populations who require ongoing medical supervision. Digital therapeutics platforms now offer physical therapy, cognitive rehabilitation, and post-stroke recovery programs through AI-driven virtual assistants and interactive exercises. These innovations reduce the need for frequent hospital visits, making healthcare more convenient and accessible.

The shift toward preventive and long-term digital health solutions will reduce the burden on Vietnam’s hospitals while improving patient engagement. As the country’s chronic disease prevalence rises, integrating DTx and RPM into standard care models will be essential for improving treatment adherence and overall population health.

Segmental Insights

Therapeutic Application Insights

Based on the category of Therapeutic Application, the Stroke segment emerged as the fastest growing segment in the China Neurovascular Devices Market in 2024. The Chinese government has prioritized stroke prevention and treatment through initiatives like the National Stroke Prevention and Control Project, which supports early diagnosis, public awareness, and the expansion of specialized stroke centers. These efforts are facilitating early interventions and expanding the market for neurovascular devices.

Mechanical thrombectomy has become the gold standard for acute ischemic stroke intervention. Devices such as stent retrievers and aspiration catheters are witnessing exponential growth due to their ability to quickly restore blood flow with high success rates. China's increasing number of qualified neurointerventionists and expanding use of stroke triage networks (e.g., "stroke green channels") are accelerating the procedure’s adoption. Reimbursement for stroke-related procedures is expanding under China’s basic medical insurance programs, particularly in urban areas. Additionally, the growth of tertiary care hospitals and comprehensive stroke units is improving access to advanced neurovascular interventions, creating strong demand for stroke-targeted devices. These factors are expected to drive the growth of this segment.

Download Free Sample Report

Regional Insights

East China emerged as the largest market in the China Neurovascular Devices Market in 2024, holding the largest market share in terms of value. East China is home to some of the country’s most prestigious tertiary hospitals and research institutions, particularly in cities like Shanghai, Nanjing, and Hangzhou. These facilities are equipped with state-of-the-art neurointerventional suites and are early adopters of advanced neurovascular devices such as stent retrievers, flow diverters, and coiling systems. The region’s dense urban population and aging demographic profile have resulted in a high incidence of stroke-related conditions, creating consistent demand for neurovascular interventions. The growing burden of ischemic and hemorrhagic stroke particularly among the elderly is fueling procedural volumes and, in turn, accelerating device consumption.

Local governments in East China actively promote medical innovation and hospital upgrading through health reform pilots and funding grants. Additionally, the region’s well-developed biomedical R&D ecosystem, particularly in Shanghai, supports local manufacturing and clinical validation of neurovascular technologies, further strengthening market accessibility and localization efforts. With increased awareness among both patients and clinicians, there is a strong shift toward minimally invasive neurointerventions. The region leads in the implementation of mechanical thrombectomy, aneurysm embolization, and carotid stenting all of which require advanced neurovascular devices.

Recent Developments

• In November 2024- MicroPort NeuroTech (Shanghai) Co., Ltd., a subsidiary of MicroPort NeuroScientific, has successfully completed the first post-market implantation of its next-generation Tubridge™ Plus Flow Diverter (Tubridge™ Plus) in China. This milestone marks the initial clinical deployment of the device following regulatory approval and demonstrates the company’s advancing role in commercializing domestically developed neurovascular technologies for the treatment of complex intracranial aneurysms.
• In March 2024, Zylox-Tonbridge announced a strategic partnership with Avinger, a U.S.-based commercial-stage company specializing in intravascular image-guided, catheter-based systems for vascular disease treatment. Under the terms of the agreement, Zylox-Tonbridge will hold exclusive rights to localize, manufacture, and commercialize Avinger’s full product portfolio across Greater China including Mainland China, Hong Kong, Taiwan, and Macau. Additionally, the partnership includes a technology transfer arrangement, enabling Zylox-Tonbridge to leverage its cost-efficient manufacturing capabilities to support Avinger’s global distribution efforts outside Greater China, reinforcing both companies’ expansion strategies.   

Key Market Players

• Zylox-Tonbridge
• MicroPort Scientific Corporation
• Medtronic
• Terumo (China) Holdings Co., Ltd.
• Integra LifeSciences Holdings Corporation
• Genesis MedTech
• ACANDIS GmbH
• Stryker

Report Scope:

In this report, the China Neurovascular Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• China Neurovascular Devices Market, By Device:

o   Cerebral Embolization and Aneurysm Coiling Devices

o   Cerebral Angioplasty and Stenting Systems

o   Neurothrombectomy Devices

o   Support Devices

o   Trans Radial Access Devices

• China Neurovascular Devices Market, By Therapeutic Application:

o   Stroke

o   Cerebral Artery

o   Cerebral Aneurysm

o   Others

• China Neurovascular Devices Market, By End User:

o   Hospitals

o   Specialty Clinics

o   Others

• China Neurovascular Devices Market, By Region:

o   North

o   East

o   North East

o   South Central

o   North West

o   South West

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the China Neurovascular Devices Market.

Available Customizations:

 China Neurovascular Devices market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).